MX2010005309A - Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor. - Google Patents

Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor.

Info

Publication number
MX2010005309A
MX2010005309A MX2010005309A MX2010005309A MX2010005309A MX 2010005309 A MX2010005309 A MX 2010005309A MX 2010005309 A MX2010005309 A MX 2010005309A MX 2010005309 A MX2010005309 A MX 2010005309A MX 2010005309 A MX2010005309 A MX 2010005309A
Authority
MX
Mexico
Prior art keywords
treatment
ion channels
oxopyrrolidin
benzenesulfonamide
thiazol
Prior art date
Application number
MX2010005309A
Other languages
English (en)
Spanish (es)
Inventor
Esther Martinborough
Dean Stamos
Timothy Neubert
Tara Whitney
Nicole Zimmermann
Mehdi Michel Djamel Numa
Aarti Sameer Kawatkar
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2010005309A publication Critical patent/MX2010005309A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MX2010005309A 2007-11-13 2008-11-12 Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor. MX2010005309A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98748507P 2007-11-13 2007-11-13
US8814108P 2008-08-12 2008-08-12
PCT/US2008/083165 WO2009064747A2 (en) 2007-11-13 2008-11-12 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain

Publications (1)

Publication Number Publication Date
MX2010005309A true MX2010005309A (es) 2010-06-25

Family

ID=40380263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005309A MX2010005309A (es) 2007-11-13 2008-11-12 Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor.

Country Status (13)

Country Link
US (3) US7994166B2 (OSRAM)
EP (1) EP2231655B1 (OSRAM)
JP (1) JP2011503112A (OSRAM)
KR (1) KR20100098396A (OSRAM)
CN (1) CN102036985A (OSRAM)
AT (1) ATE522526T1 (OSRAM)
AU (1) AU2008321137A1 (OSRAM)
CA (1) CA2705336A1 (OSRAM)
IL (1) IL205697A0 (OSRAM)
MX (1) MX2010005309A (OSRAM)
NZ (1) NZ585332A (OSRAM)
RU (1) RU2010123781A (OSRAM)
WO (1) WO2009064747A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
CN101218226A (zh) * 2005-05-16 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
RU2008113836A (ru) * 2005-09-09 2009-10-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов
WO2007050522A1 (en) * 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
US8193194B2 (en) 2007-05-25 2012-06-05 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
ES2377172T3 (es) * 2007-11-13 2012-03-23 Vertex Pharmaceuticals Incorporated Derivados heterocíclicos como moduladores de canales iónicos
RU2010123781A (ru) 2007-11-13 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли
KR20110025855A (ko) * 2008-07-01 2011-03-11 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 헤테로사이클릭 유도체
JP6215230B2 (ja) * 2012-01-16 2017-10-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド
KR20150065177A (ko) 2012-10-12 2015-06-12 에프. 호프만-라 로슈 아게 치환된 페닐카르바메이트 화합물
WO2014060341A1 (en) 2012-10-16 2014-04-24 F. Hoffmann-La Roche Ag Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
EP3541373B1 (en) 2016-11-17 2023-11-01 Merck Sharp & Dohme LLC Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
SG11202000217QA (en) 2017-07-21 2020-02-27 Antabio Sas Chemical compounds
CN113008999B (zh) * 2019-12-19 2024-08-23 重庆药友制药有限责任公司 一种分离测定氟比洛芬酯中2种基因毒性杂质的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU2004240885A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type I
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
KR20060073930A (ko) 2003-08-08 2006-06-29 버텍스 파마슈티칼스 인코포레이티드 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체
JP2007261945A (ja) * 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体
JP2008540539A (ja) 2005-05-10 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャンネルの調節因子としての二環系誘導体
CN101218226A (zh) * 2005-05-16 2008-07-09 沃泰克斯药物股份有限公司 作为离子通道调控剂的二环衍生物
JP5112297B2 (ja) 2005-05-20 2013-01-09 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なキノリン誘導体
KR20080019693A (ko) * 2005-06-09 2008-03-04 버텍스 파마슈티칼스 인코포레이티드 이온 채널 조절인자로서의 인단 유도체
RU2008113836A (ru) 2005-09-09 2009-10-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов потенциалозависимых ионных каналов
CA2624831A1 (en) * 2005-10-12 2007-04-26 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
WO2007050522A1 (en) 2005-10-21 2007-05-03 Vertex Pharmaceuticals Incorporated Derivatives for modulation of ion channels
CA2633653A1 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
US8193194B2 (en) 2007-05-25 2012-06-05 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
ES2377172T3 (es) * 2007-11-13 2012-03-23 Vertex Pharmaceuticals Incorporated Derivados heterocíclicos como moduladores de canales iónicos
RU2010123781A (ru) 2007-11-13 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли
KR20110025855A (ko) 2008-07-01 2011-03-11 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서의 헤테로사이클릭 유도체

Also Published As

Publication number Publication date
CN102036985A (zh) 2011-04-27
WO2009064747A3 (en) 2010-08-19
ATE522526T1 (de) 2011-09-15
RU2010123781A (ru) 2011-12-20
US8841282B2 (en) 2014-09-23
IL205697A0 (en) 2010-11-30
NZ585332A (en) 2012-05-25
US20120010416A1 (en) 2012-01-12
JP2011503112A (ja) 2011-01-27
AU2008321137A1 (en) 2009-05-22
CA2705336A1 (en) 2009-05-22
US20130338119A1 (en) 2013-12-19
EP2231655A2 (en) 2010-09-29
US20090131440A1 (en) 2009-05-21
EP2231655B1 (en) 2011-08-31
WO2009064747A2 (en) 2009-05-22
US7994166B2 (en) 2011-08-09
KR20100098396A (ko) 2010-09-06

Similar Documents

Publication Publication Date Title
MX2010005309A (es) Derivados de 4-(3-(2-(fenil)morfolino)-2-oxopirrolidin-1-il-n-(tia zol-2-il)bencensulfonamida y compuestos relacionados como moduladores de canales ionicos para el tratamiento del dolor.
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
MX2010003009A (es) Piridil sulfonamidas como moduladores de canales ionicos.
ZA201003352B (en) Heterocyclic derivatives as modulators of ion channels
IL187382A0 (en) Bicyclic derivatives as modulators of ion channels
MX2010003865A (es) Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2010003866A (es) Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
MX2010003864A (es) Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
MX2009011816A (es) Derivados de piridina.
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
NO20060518L (no) Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler
MY161991A (en) Proteasome inhibitors
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MX2008005398A (es) Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
MX2009011810A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MX2009012719A (es) Tiazoles y pirazoles utiles como inhibidores de cinasa.
MXPA05010496A (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.

Legal Events

Date Code Title Description
FG Grant or registration